BOSTON (June 14, 2024) — Servier Pharmaceuticals, a leader in oncology committed to delivering transformative new therapies to patients, announced today that The Boston Business Journal (BBJ) named the company a Best Places to Work for the fourth consecutive year. This list is the BBJ’s exclusive ranking of Massachusetts companies that have built outstanding work environments.
“I am honored to see the Boston Business Journal recognize Servier as a ‘Best Places to Work’ for the fourth consecutive year,” said David K. Lee, Chief Executive Officer at Servier Pharmaceuticals. “People and our relationships with each other mean more to me than anything else, and, at Servier, they are our most important asset. Our employees embody our mission and are the driving force behind our continued rapid success. I am inspired every day by their steadfast commitment to changing the lives of the patients we serve.”
Servier established Boston as its U.S. headquarters in 2018. Since then, the company has more than doubled its portfolio, quadrupled its employee base, and brought transformative new therapies to patients living with cancer. Being governed by a Foundation allows Servier to be truly patient-centric, prioritizing the long-term welfare of patients.
“This recognition is a testament to the supportive, inclusive, and dynamic work environment we’ve created at Servier,” said Nick Stefos, Head of Human Resources at Servier Pharmaceuticals. “We are incredibly proud of this achievement and remain committed to nurturing a culture where every employee can thrive while contributing to our shared mission.”
About Servier Pharmaceuticals
Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.
As a leader in oncology, Servier is committed to finding solutions that will address today’s challenges. The company’s oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients.
Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies. With the company’s commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.
For more information: www.servier.us.
Press Contact:
Servier Pharmaceuticals (U.S.)
Erin Smith
Erin.Smith@servier.com